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Background: In atrial ﬁbrillation (AF), VV optimization of biventricular pacemakers can be examined in isola-
tion. We used this approach to evaluate internal validity of three VV optimization methods by three criteria.
Methods and results: Twenty patients (16 men, age 75±7) in AF were optimized, at two paced heart rates, by
LVOT VTI (ﬂow), non-invasive arterial pressure, and ECG (minimizing QRS duration). Each optimization
method was evaluated for: singularity (unique peak of function), reproducibility of optimum, and biological
plausibility of the distribution of optima.
The reproducibility (standard deviation of the difference, SDD) of the optimal VV delay was 10 ms for pres-
sure, versus 8 ms (p=NS) for QRS and 34 ms (pb0.01) for ﬂow.
Singularity of optimum was 85% for pressure, 63% for ECG and 45% for ﬂow (Chi2=10.9, pb0.005).
The distribution of pressure optima was biologically plausible, with 80% LV pre-excited (p=0.007). The dis-
tributions of ECG (55% LV pre-excitation) and ﬂow (45% LV pre-excitation) optima were no different to ran-
dom (p=NS).
The pressure-derived optimal VV delay is unaffected by the paced rate: SDD between slow and fast heart rate
is 9 ms, no different from the reproducibility SDD at both heart rates.
Conclusions: Using non-invasive arterial pressure, VV delay optimization by parabolic ﬁtting is achievable
with good precision, satisfying all 3 criteria of internal validity. VV optimum is unaffected by heart rate. Nei-
ther QRS minimization nor LVOT VTI satisfy all validity criteria, and therefore seem weaker candidate modal-
ities for VV optimization. AF, unlinking interventricular from atrioventricular delay, uniquely exposes
resynchronization concepts to experimental scrutiny.© 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license. 1. Introduction
Of all the aspects of optimization, VV optimization of biventricular
pacing is the most challenging. The term “Cardiac Resynchronization
Therapy” itself implies that dyssynchrony between regional ventricu-
lar contraction is the disease being treated: if this is true then it must
matter what interventricular delay is programmed. Although the
PROSPECT trial [1] showed no worthwhile prediction of echocardio-
graphic response from echocardiographic markers of dyssynchrony,
clinical progress over months in patients with heart failure isirculatory Health, 59-61 North
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nder CC BY-NC-ND license. dependent on a very wide spectrum of intercurrent environmental,
neurohormonal, compliance, dietary, infectious, arrhythmic, ischae-
mic, and psychological phenomena, and the measurement techniques
for dyssynchrony have very large beat-to-beat variability [2,3] so
their failure to correlate with anything is unsurprising [4] and there-
fore uninﬂuential on the speciﬁc question of whether ventricular tim-
ings make any detectable difference in an environment where all else
is unchanged.
Even this tightly-described question is difﬁcult to answer. First,
the effect of changing the VV delay is less than that of changing the
AV delay [5], making it even more difﬁcult to separate the genuine ef-
fect (signal) of changing a setting, from random variability (noise)
[6]. Because the effect of VV optimization may be 5–10 times smaller
than that of CRT implantation, an endpoint study would have to be
25–100 times larger than, for example, CARE-HF, to give reliable re-
sults. Second, changing the VV delay in patients with sinus rhythm
955A. Kyriacou et al. / International Journal of Cardiology 167 (2013) 954–964inevitably affects the AV delay on one side of the heart or the other, so
it is impossible to know for certain if any effects seen come from the
AV or VV changes, or both [7].
For these reasons, whilst the beneﬁts of AV optimization are well
established [8–10], the beneﬁts of VV optimization are less well un-
derstood. Although a few small studies have suggested that optimiza-
tion of the VV delay may provide beneﬁts beyond AV optimization
alone [8,11,12], clinical trials have so far failed to show signiﬁcant
clinical improvements at 6 months [13–15].
In atrial ﬁbrillation however, there is no AV delay to confound VV
optimization (Fig. 1). Therefore any impact of a VV delay change is a di-
rect consequence of that change in the VV delay alone. In this study, we
recruited patients in AF as a model for ‘pure’ VV optimization.
As it is not yet realistic to look for differences in clinical outcomes
between different markers of optimization, a practical way to com-
pare these is to evaluate the relative performance of each method,
head to head, in an identical patient group. Any marker of optimality
used to select a pacemaker setting must fulﬁl three essential features
that can be efﬁciently assessed:
1) Singularity; there should be only one region of optimality, with
progressively poorer function as settings are changed away from
this region. If the optimal region is at one extreme of settings,
then there could be one rather than two regions of optimality,
but it is not possible for there to be two regions of optimality sep-
arated by a region of non-optimality.Fig. 1. Each circle shows 1 cardiac cycle in sinus rhythm, with electrical activity shown on th
and the A-wave is active ventricular ﬁlling. For example, in a Medtronic pacemaker, selectin
stant, increases the actual effective AV delay to left-sided pacing, because the programmed
wave, which can only occur after the ventricle ﬁnishes ejecting, therefore occurs later (in rel
selecting LV pre-excitation has the mirror image effect on the right side of the heart. Other
mains: the VV delay cannot be changed without changing the mechanical AV delay on one
include an occult element of AV optimization.2) Reproducibility; if the optimization process is repeated immediate-
ly with a new operator blinded to the previously found optimal
setting, the newly-found optimum should be very similar.
3) Plausibility; the distribution of optimum settings should not con-
tradict established physiological principles. For example, fre-
quently ﬁnding apparent VV optima with large RV pre-excitation
would contradict the principle in resynchronization that the LV
wall should usually be paced simultaneously with, or earlier
than, the RV.
In this study, we tested three different optimization markers that
might be used [16–18] to identify a VV delay optimum in the AF co-
hort, in which there was no possibility of VV delay alteration causing
confounding changes in the AV delay. The markers tested were ECG
(QRS duration minimization), LVOT VTI maximization (ﬂow) and
non-invasive arterial BP (pressure).
2. Methods
2.1. Patients
Twenty patients (16 men, mean age 75±7 years) in atrial ﬁbrillation, with a CRT
device were enrolled in the study. Average NYHA class was 2.4±0.5. The underlying
cause of heart failure was ischemic heart disease in 10, dilated cardiomyopathy in
8 and valvular disease in 2 patients.
The study was approved by the Imperial College Healthcare NHS Trust ethics com-
mittee, and all patients provided written informed consent.e inside and mechanical activity on the outside. The E-wave is passive ventricular ﬁlling
g RV pre-excitation instead of simultaneous, while keeping programmed AV delay con-
AV delay is to the “ﬁrst lead to be activated” in this manufacturer's convention. The E-
ation to the A-wave) on the left side than it did before the VV delay change. Conversely,
manufactures have different conventions for labelling the delays, but the constraint re-
side of the heart or the other. All apparent VV optimizations in sinus rhythm therefore
Table 1
Baseline patient characteristics.
Demographics Mean and SD or n (%)
Age 75 SD 7
Age range 58–91
Male 16 (80%)
Aetiology
Ischaemic 10 (50%)
Dilated 8 (40%)
Valvular 2 (10%)
NYHA class
II 13 (65%)
III 7 (35%)
LVEF (%) 31 SD 13
Medications
ACEi/ARB 19 (95%)
β-blocker 17 (85%)
Diuretic 17 (85%)
Spironolactone 8 (40%)
Digoxin 12 (60%)
956 A. Kyriacou et al. / International Journal of Cardiology 167 (2013) 954–9642.2. Study design
Measurements, using transthoracic echocardiography, ﬁnger photoplethysmogra-
phy (Finometer) and electrocardiography, were made at six VV delays (−40 ms,
−20 ms, 0 ms, 20 ms, 40 ms and 60 ms, where a negative VV delay indicates right ven-
tricular pre-excitation). All patients were optimized at 2 heart rates; at a slow paced
rate just above the rate of intrinsic conduction (always ensuring 100% biventricular
pacing); and at a faster paced rate (mean of 27±7 bpm above slow). Optimization
was repeated within one hour using all three optimization modalities, at both heart
rates.
Because beat-to-beat biological noise exceeds between-setting variability, often by
a large margin, it is not possible to reliably deﬁne the optimum as the setting which
generates the highest observed pressure or ﬂow (or smallest QRS duration) [3,18,19].
Instead, for each variable a curve-ﬁtting approach was used which minimises the im-
pact of noise and makes maximal use of scarce signal [6].
2.3. Finger photoplethysmography
Beat-to-beat blood pressure was recorded using a Finometer (Finapres Medical
Systems, Amsterdam, Netherlands). Optimization of the VV delay was performed
using a protocol described in previous work [5,6,20–23] and algorithmically similar
that used by others [24] Transitions to the tested VV delay from a ﬁxed reference VV
delay (of 0 ms) were performed. A minimum of eight transition replicates were
recorded for each tested VV delay. Within each replicate, the 10 beats after the transi-
tion were compared with the 10 beats before the transition, to calculate the relative
systolic blood pressure. Analysis was performed using software based on the Matlab
platform (MathWorks, Natick, MA, USA) but could equally have been carried out
with a standard spreadsheet. The relationship was ﬁtted to a parabola by standard
least-squares regression, and the optimum VV delay deﬁned by interpolation as the
position of the peak of the parabola [6].
2.4. Echocardiography
Images were obtained using a ProSound SSD-5500SV system (Aloka, Tokyo, Japan),
with the operator blinded to the VV delays which were randomly programmed by a
second operator. Six consecutive beats, of left ventricular outﬂow tract (LVOT) and mi-
tral valve (MV) ﬂow were acquired with the patient positioned in the dorsal decubitus
or left lateral decubitus position, at passive end expiration. The average of the 6 beats
was taken as the value for that setting. Medcon software (McKesson, San Francisco,
USA) was used for ofﬂine analysis. The myocardial performance index (MPI) [25]
was calculated by measuring the time from cessation to the start of mitral ﬂow
(A) and left ventricular ejection time (ET). Therefore, IVCT+IVRT=A−ET and as
a result MPI=(A−ET)/ET.
The VTI optimum was deﬁned by parabolic ﬁtting of the average values for each
setting, as the interpolated position of the greatest VTI.
2.5. Electrocardiography
12 lead ECG traces were obtained using a MAC 1200 ST system (GE Healthcare,
Chalfont St Giles, UK) at each VV delay and at both heart rates for all patients. In this
system, the QRS width is calculated using synchronously sampled and time aligned
data across 12 leads, measuring the time from ﬁrst deﬂection of the median QRS com-
plex in any lead to the latest deﬂection in any lead. The average QRS duration from 2
recordings was used for each setting. Recordings which contained ventricular ectopics
were excluded and the 12 lead ECG repeated. The optimum was deﬁned by the same
principle as above, as the interpolated position of the narrowest QRS.
2.6. Statistical analysis
Reproducibility and agreement of the parabola-determined [5] optima by different
optimization methods were assessed by using Bland–Altman plots and the standard
deviation of the difference (SDD) between the optimal VV delays. Paired comparisons
of normally-distributed continuous variables were made using Student's paired t test.
Paired comparisons of non-normally-distributed continuous variables were made
using Wilcoxon's matched-pairs signed rank test. A p value of b0.05 was taken as sta-
tistically signiﬁcant. Statview 5.0 (SAS Institute Inc., Cary, NC) was used for statistical
analysis.
All studied patients are presented. All data are presented. We believe these
ﬁndings are representative of patients with CRT and AF and know of no undisclosed
biases in recruitment, analysis or presentation. DPF is guarantor of scientiﬁc integrity
[34].3. Results
20 patients were included in this study. Their characteristics are
shown in Table 1.3.1. Criterion 1: Singularity—one optimum region
All 20 patients’ optimization curves for LVOT VTI maximization,
pressure maximization and QRS minimization are shown in Figs. 2,
3 and 4, respectively.
Only instances in excess of 50% were evidence of the physiological
validity of a measure, as shown in Table 2. The percentage of singularity
was 85% for pressure, 63% for QRS and 45% for ﬂow. The extent of singu-
larity was signiﬁcantly different between modalities (Chi2=10.9,
pb0.005). The percentage of singularity for all parameters tested is
shown in Fig. 5.
3.2. Criterion 2: Reproducibility—the same optimum when retested
Reproducibility of optimization was quantiﬁed by the standard
deviation of the difference (SDD). This is shown for all measures at
the slow and fast heart rates in Tables 3 and 4, respectively.
Optimization by LVOT VTI showed a wide scatter between succes-
sive optima (SDD 35.4 ms). Other echo markers also performed poor-
ly if considered as potential methods of optimization. The most
reproducible methods of optimization were SBP maximization (SDD
9.4 ms) and QRS minimization (SDD 6 ms). Bland–Altman plots for
the three key modalities being studied (ﬂow, pressure and QRS) are
shown in Fig. 6.
3.3. Criterion 3: Plausibility of the distribution of optima
The distribution of optimal VV delays at the fast heart rate, of all 3
optimization methods is shown in Fig. 7. By pressure, the optimum
was often near a 0 ms VV delay: 75% were within 20 ms of zero. A sig-
niﬁcant majority (80%, p=0.007) of pressure optima had a degree of
LV pre-excitation.
In contrast, the ﬂow and QRS optima tended to be further away
from zero: only 60% and 50%, respectively were within 20 ms of
zero. Moreover, the proportion of optima by these modalities that
had a degree of LV pre-excitation was not signiﬁcantly different
from chance (45% for ﬂow and 55% for QRS, p=NS in each case).
3.4. Agreement of the optimal VV delay between LVOT VTI, QRS width and
beat-to-beat systolic blood pressure
Incidentally available was agreement between modalities, also
displayed in Tables 3 and 4. Agreement between methods was poor,
typically with a SDD of the order of 40 ms, meaning that if a method
gave an optimum of X, the other method would be expected 95% of
the time to give an optimum between X-80 ms and X+80 ms, a
very wide range.
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Fig. 2. First (black) and second (grey) sessions of optimization on the same day, using LVOT VTI at each VV delay (RV 40 to LV 60), for all 20 patients. A parabola was ﬁtted in all
optimization sessions and the peak of the parabola was considered to represent the optimal VV delay (optimum = largest VTI).
957A. Kyriacou et al. / International Journal of Cardiology 167 (2013) 954–964We should bemindful that no irreproduciblemethod can ever agree
with any other method [4]. Thus, it could be argued that the only scien-
tiﬁcally valuable numbers on the table are the principal diagonal (re-
producibility of each modality) and the twin values of “43.9” in the
bottom right corner, which shows the between-modality test for the
only two modalities (QRS minimization and SBP maximization) that
show good reproducibility.4. Discussion
This study evaluated the performance of three potential ap-
proaches for VV optimization, using the three key criteria for internal
validity of an optimization. Of the approaches tested, optimization by
pressure appears to offer all 3 criteria: singularity, reproducibility and
biological plausibility. QRS minimization offers singularity and
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Fig. 3. First (black) and second (grey) sessions of optimization on the same day, using non-invasive SBP at each VV delay (RV 40 to LV 60) for all 20 patients. A parabola was ﬁtted in
all optimization sessions and the peak of the parabola was considered to represent the optimal VV delay (optimum = highest relative SBP).
958 A. Kyriacou et al. / International Journal of Cardiology 167 (2013) 954–964reproducibility, but the distribution of optimum settings obtained ap-
pears biologically implausible. Optimization by ﬂow performed disap-
pointingly on all 3 criteria of internal validity.
4.1. Three criteria for internal validity
Reproducibility is a key criterion for any method of optimization. If
an individual patient is given multiple discrepant proposed ‘optima’
in rapid succession by a single method, most of these apparent opti-
ma must be incorrect. While reproducibility alone is not sufﬁcient cri-
terion to judge an optimization approach to be internally valid, it is a
necessary one.Singularity indicates that there is only a single region which ap-
pears to be optimal, rather than two optimal regions separated by
non-optimality. This is relevant because the principle of CRT is to im-
prove cardiac function by bringing the walls of the heart into more
closely coordinated times of contraction (although not necessarily
to VV 0 ms). Moving away from this optimal timing of contraction
in either direction should worsen cardiac function. In some cases
(when the true optimal region is at the extremes of the range of
tested settings) there might reasonably be only one non-optimal re-
gion, but singularity can still be tested by the shape of the curve. Be-
cause the shape of the curve should be almost ﬂat at the optimal
region, becoming steep as one moves away, ﬁtting a parabola will
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Fig. 4. First (black) and second (grey) sessions of optimization on the same day, using 12-lead ECG QRS width, at each VV delay (RV 40 to LV 60) for all 20 patients. A parabola was
ﬁtted in all optimization sessions and the trough of the parabola was considered to represent the optimal VV delay (optimum = narrowest QRS).
959A. Kyriacou et al. / International Journal of Cardiology 167 (2013) 954–964still verify singularity (i.e. the orientation of curvature would indicate
that there would have been 2 non-optimal regions, if more settings
beyond the optimal had been tested).
Biological plausibility of the distribution of the obtained optima is
the ﬁnal criterion. It is less fundamental than the others because it re-
lies on separately-acquired beliefs of what distribution of optima is
expected. CRT is generally accepted to exert beneﬁts by decreasing
rather than increasing dyssynchrony of the myocardial walls. It istherefore rational to expect the distribution of the optima to show
that for many patients, their optimum setting is near to the VV
delay of 0 ms, with only few patients being at an optimum with
marked pre-activation of one lead. It is left, rather than right, bundle
branch block in which the salutary effects of biventricular pacing are
most prominent, and invasive studies [10,26–28] have shown that left
ventricular pacing can achieve most of the effect of biventricular
pacing but right ventricular pacing cannot. These prior observations
Table 2
Comparison of optima singularity betweenmodalities. Optimization by pressure provided
a high degree of optima singularity (expressed in % above chance alone). QRS optimization
had a reasonable degree of singularity, butﬂowoptimizationwas the least convincing. The
difference in degrees of singularity between modalities was signiﬁcant (pb0.005).
Optimization
method
Number of
optimizations,
out of 40,
having a
single optimal
region
Number
out of 80
Degree of
singularity,
beyond
expectation
of
chance
Slow
rate
Fast
rate
Overall
Pressure 36 38 74 85%
Flow 30 28 58 45%
QRS 35 30 65 63%
Difference between modalities: Chi2: 10.9
p value: b0.005
960 A. Kyriacou et al. / International Journal of Cardiology 167 (2013) 954–964are reasons to expect the VV delay optimum to more often involve
pre-activation of the left ventricle than the right.
4.2. Internal validity as an endpoint in a “basic science” of optimization
This study speciﬁcally focussed on the three key characteristics of
internal validity of an optimization approach. We did this because
these are essential criteria that may be deﬁnitively established in con-
trolled circumstances, and which enables early identiﬁcation of po-
tentially unsuitable optimization approaches so that any large
clinical event trials can focus resources appropriately.
In this study, only optimization by pressure fulﬁlled all 3 criteria.
4.3. Does VV delay matter at all?
The term “resynchronization”—which can only mean interventri-
cular because atrioventricular timing is never synchronous in health
—implies that VV timing matters, but appears contradicted by data
[29]. For example, the prospectively-enrolled PROSPECT study
appeared to contradict the belief that mechanical dyssynchrony is rel-
evant; and several well-conducted studies of VV optimization appear
to contradict the belief that interventricular delay matters at all.
However, the fact that various imaging markers in PROSPECT were
mutually contradictory guarantees that most of themmust fail to pre-
dict beneﬁt. That they all failed highlights the fact that the study's
process of choosing markers was arbitrary, based on availability
rather than any detectable scientiﬁc process (which would screen-25 -5 -5 25-5 -20 15 25
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Fig. 5. By random chance alone, 50% of the parabolic curves ﬁtted would be expected to be in
orientated curves needs be transformed to 2(x−50) to obtain the proportion in excess of chanc
perfect orientation. SBP had a signiﬁcantly higher percentage of correctly orientated optimizatout those with poor test–retest reproducibility). PROSPECT therefore
casts no light on whether interventricular delay matters.
The 3 VV optimization studies are also less decisive than might be
assumed. First, the Decrease-HF [14] study demonstrated that pro-
gramming VV delay according to a formula obtained purely during in-
trinsic conduction gave no beneﬁt, but it was not a process of
measuring values at different settings to select an optimum. Second,
the Rhythm II ICD [13] study used echocardiographic maximization
of LVOT VTI, and found no beneﬁt, did not report whether the method
of optimization had good test–retest reproducibility: without know-
ing this we cannot tell whether it was VV delay that was unimportant
or the optimization process that was unreliable [3]. Third, the Insync
III [15] study was not a randomized trial but a comparison with his-
torical controls. Moreover, although it conducted more than one opti-
mization per patient, the test–retest reproducibility data remains at
present undisclosed. Without this information on whether patients
retested had the same optima as before, or only just ﬁtting the same
overall distribution, conclusions cannot yet be drawn.
4.4. Need for, and plausibility of, reports of clinical endpoint effects of
optimization
Some interventions, such as device implantation, impose a large
cost and substantial risk for the patient, and therefore judgements
on whether to carry them out universally are dependent on the re-
sults of randomised trials of clinical outcomes. The ﬁnancial invest-
ment required for these trials typically runs into many millions of
dollars, so they are mainly carried out when an industrial organisa-
tion, hoping to proﬁt from the conclusions, is willing to invest.
But cliniciansmakemany choices. Not all are “whether” to do some-
thing extra which might have a cost or impose risk. Others are “which”
of many options: selection of pacemaker settings is an example of such
a choice. For such decisions, awaiting an adequately-powered industry-
supported clinical endpoint trial may be a forlorn vigil.
In this study we did not attempt to acquire clinical endpoint data
from these differences in VV delay. We made this choice because the
effect was not as large as the effect of simply switching on a CRT device,
and so the number of patients required for the clinical endpoints to be
realistically informative—which rises with 1/(effect size) 2—would be
very large.
Instead we concentrated on haemodynamic responses whose re-
producibility is easily veriﬁable by any reader and which avoid the il-
lusions of response arising from using optimization data itself to
measure response [3], and accidentally generated correlations arising
from confounding exclusions or optimistic reanalysis [30]. We are
conﬁdent our ﬁndings will stand the test of time.45 50 60 80 8020 40 55 35 90
MPI LVOT VTI MV VTI QRS SBP
the physiologically meaningful orientation. Therefore the raw percentage (x) of correctly
e. On this scale, Ø represents the average expectation by chance alone, and 100 represents
ion curves than LVOT VTI and QRS, at both the slow and fast heart rates.
Table 3
Agreement of optima between modalities at the slow heart rate. Values on the principal diagonal of the table indicate reproducibility (in bold) of the optimum using the same modality
twice; other values indicate the agreement betweenmodalities. All agreements are quantiﬁed as the standard deviation of difference (SDD,ms) between the two optima obtained, in the
20 subjects.
LVOT VTI QRS to LVOT VTI LVOT ejection time MV VTI MV VTI to QRS MV ejection time MPI QRS SBP
Echocardiography
LVOT VTI 34.0 41.1 64.7 34.3 43.6 56.9 31.4 44.8 37.0
QRS to LVOT VTI 41.1 39.2 62.6 43.1 51.6 49.5 35.8 23.8 36.1
LVOT ejection time 64.7 62.6 58.1 57.9 67.9 51.5 67.5 60.6 61.7
MV VTI 34.3 43.1 57.9 46.8 46.4 59.2 38.7 42.0 44.6
MV VTI to QRS 43.6 51.6 67.9 46.4 39.8 52.9 51.4 49.0 47.2
MV ejection time 56.9 49.5 51.5 59.2 52.9 42.2 62.8 57.7 53.0
MPI 31.4 35.8 67.5 38.7 51.4 62.8 55.8 39.0 33.2
Electrocardiography
QRS width 44.8 23.8 60.6 42.0 49.0 57.7 39.0 8.0 33.3
Finometer
SBP 37.0 36.1 61.7 44.6 47.2 53.0 33.2 33.3 10.2
LVOT indicates left ventricular outﬂow tract; MV, mitral valve; VTI, velocity time integral; MPI, myocardial performance index; SBP, acute change in systolic blood pressure.
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There is a strong a priori rationale for the use of LVOT VTI (ﬂow) as
a marker of cardiac function, for optimization. Given that the diame-
ter of the LVOT remains constant, changes in stroke volume are solely
dependent on velocity and duration of blood ﬂow. Therefore, the
LVOT VTI is a perfect index of stroke volume which in turn is, in prin-
ciple, a very plausible marker of cardiac function since other charac-
teristics are kept constant.
In this study, conducted in a research setting with less time con-
straint than occurs in routine clinical practice, wemeasured a number
of LVOT VTIs (6 beats) that would be considered large by routine clin-
ical standards. The reason was to improve the signal-to-noise ratio
and therefore improve the reproducibility of the optimal VV delay
[3]. Resource constraints often limit routine clinical practice to only
3, 2 or even 1 beat.
Despite taking this step, LVOT VTI optimization performed poorly
on all counts of internal validity. This may be an explanation for the
inconsistent ﬁndings reported by other studies testing clinical out-
comes following VV optimization [13–15].
Singularity, (test–retest) reproducibility and plausibility of the op-
timum have rarely been commented upon in studies of LVOT VTI
optimization.
4.6. QRS minimization as a modality for VV optimization
QRS width is a highly reproducible measurement that is quickly
and cheaply acquired, potentially automatically, and it avoids the
problems of needing good echocardiographic windows and a trained
operator with enough time to perform and analyse a lengthy series ofTable 4
Agreement of optima between modalities at the fast heart rate. Values on the principal diagon
twice; other values indicate the agreement between modalities. All agreements are quantiﬁed
in the 20 subjects.
LVOT VTI QRS to LVOT VTI LVOT ejection time
Echocardiography
LVOT VTI 35.4 46.9 43.1
QRS to LVOT VTI 46.9 27.7 46.6
LVOT ejection time 43.1 46.6 39.2
MV VTI 49.7 47.3 58.7
MV VTI to QRS 51.9 69.5 68.7
MV ejection time 52.1 59.4 54.1
MPI 47.8 47.8 56.2
Electrocardiography
QRS width 41.4 43.6 48.4
Finometer
SBP 45.3 53.2 54.6
LVOT indicates left ventricular outﬂow tract; MV, mitral valve; VTI, velocity time integral; Mmeasurements. There are studies showing some association between
a reduction in the QRS width and clinical beneﬁts [31,32].
However, our ﬁndings showed that although reproducible and
generally singular, QRS minimization frequently proposed optimal
VV delays that had marked right ventricular pre-activation (Fig. 7).
This is not biologically plausible if the current understanding of cardi-
ac resynchronization process is correct.
Moreover, in our study, QRS and pressure optima agreed poorly.
Because we have quantitative data on reproducibility of these tech-
niques in the same patients at the same session, we know that the
discrepancy between methods is not due to imprecision of our ability
to establish each optimum, but rather that the two optima are provid-
ing fundamentally contradictory information.
It is inescapable from our data that QRS minimisation deﬁnitely
results in a lower blood pressure. Forced to choose between a pres-
sure maximum and a QRS minimum, our interpretation is that the
pressure maximum is both intrinsically a better physiological target
as well as showing a biologically more plausible distribution of VV op-
tima. The numerous elements contributing to mechanical dyssyn-
chrony, and cardiac function overall, go far beyond QRS width, as
has been documented in several studies [33,34]. Therefore, even
though wide QRS may predict beneﬁt for CRT [1,35–37], ﬁrst princi-
ples do not require that QRS minimization must be the ideal approach
to VV optimization.
4.7. VV optimum unchanged by heart rate, if measured reproducibly
Using pressure optimization, the internally valid method, we con-
cluded that heart rate had no discernible effect on optimal VV delay.
This not to say that the observed optimum was the same at slow asal of the table indicate reproducibility (in bold) of the optimum using the same modality
as the as standard deviation of difference (SDD, ms) between the two optima obtained,
MV VTI MV VTI to QRS MV ejection time MPI QRS SBP
49.7 51.9 52.1 47.8 41.4 45.3
47.3 69.5 59.4 47.8 43.6 53.2
58.7 68.7 54.1 56.2 48.4 54.6
38.7 56.6 64.6 46.1 33.1 38.0
56.6 31.7 58.2 57.6 51.1 40.6
64.6 58.2 54.5 69.2 59.9 52.7
46.1 57.6 69.2 45.2 48.6 42.9
33.1 51.1 59.9 48.6 6.0 43.9
38.0 40.6 52.7 42.9 43.9 9.4
PI, myocardial performance index; SBP, acute change in systolic blood pressure.
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Fig. 6. The reproducibility (standard deviation of the difference—SDD in ms) of LVOT VTI (A) is equally poor at the slow (34 ms) and fast (35 ms) heart rates. SBP reproducibility
(B) was better than LVOT VTI at slow (10 ms, pb0.01) and fast heart rates (9 ms, pb0.01). The reproducibility of the QRS width (C) was also better at slow (8 ms, pb0.01) and fast
(6 ms, pb0.01) rates.
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mum was different between slow and fast. However, this change
was as frequently an increase as a decrease, and its scatter was the
same as the test–retest scatter of individual patients’ optimal settings
at slow or fast heart rates. This means that no mechanism other than
natural biological variability (unrelated to heart rate change) is nec-
essary to explain the changes observed between heart rates. While
we cannot exclude a small heart rate effect, any such effect must be
small.
Judgement of reports of change in optimum of a pacemaker with
the passage of time or after an intervention should always be re-
served until it has a context of blinded short-term test–retest repro-
ducibility data for that optimization process.
4.8. Clinical implications
Optimization techniques vary in their ability to detect the opti-
mum reliably as we have seen in this study and have reviewed with
a generalizable framework previously [3].
If there is insufﬁcient time to perform a reliable optimization [3],
unreliable optimization should not be performed except perhaps
where mandated as part of a randomized controlled trial, or as part
of an evaluation such as this study. It consumes resources andattention; moreover it may cause clinical harm by shifting patients
away from default settings (near which the true optimum may lie
in most patients) to VV delays far away which could worsen cardiac
function. This concern is sound grounds for a clinician to leave default
VV settings unchanged until optimization methods with good reli-
ability become available locally.
Disobeying guidelines systematically takes courage if they are
well-founded [37]. However, this study provides quantitative reason-
ing and measurements—both of which can be tested afresh by any
party—to hold guideline recommendations to account. For example,
if a clinical service uses LVOT VTI to optimize the VV delay, at the
slow heart rate the scatter between repeated optimization using
ﬂow is 34 ms. This means after one optimization, the next identical
procedure will, 95% of the time, report an optimization within
±1.96×34, i.e. ±67 ms; in other words a range as wide as all the
settings tested. Clinical wisdom may prevail, preventing extreme
values being selected, but if so, what is the net effect other than ran-
dom selection amongst clinically-reasonable VV delays?
4.9. Study limitations
This studywas not designed to test the clinical beneﬁt of VV optimi-
zation, nor to attempt to separate responders from non-responders. It
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Fig. 7. LVOT VTI (A) and QRS (C) optima distributions contain a high proportion of optima
with signiﬁcant (−40 ms) RV pre-excitation. In contrast, the SBP (B) optima distribution
is more central, around VV 0 ms, and most optima are LV pre-excited.
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VV optimization relevant to internal validity.
Althoughmeasurements were performed in a teaching hospital by
experienced clinical research staff, there may be centres with greater
skills in, for example, echocardiography which might be able to
achieve better performance from ﬂow optimization (LVOT VTI) than
what we achieved. Superﬁcially, that would appear to be the case
from the fact that guidelines recommend ﬂow optimization of the
VV delay [37]. Nevertheless, we note that the guidelines do not cite
independent data on the 3 key principles of internal validity (singu-
larity, reproducibility and plausibility) of ﬂow optimization, or any
comparison of these principles between ﬂow and any other alterna-
tives, and therefore it is possible that ﬂow optimization was recom-
mended only because there appeared to be no alternative.
Ventricular ectopy was completely excluded from echocardiogra-
phy images and from QRS measurements, but not eliminated from
the semi-automated analysis of pressure optimization. This may
have adversely affected the precision of the pressure data. However,
results in terms of singularity, reproducibility and plausibility, were
still no worse for pressure than for ﬂow and QRS. The practical advan-
tage of pressure over ﬂow is that it could be monitored by automated
systems without manual beat-by-beat calculation, and therefore it is
ﬁtting that pressure measurement was calculated in this study in
the same way that might happen in a real-world clinical system oper-
ating without beat-by-beat supervision.
Optimal VV delays were calculated using data taken with the pa-
tient lying down, and this may not necessarily reﬂect the optimal
VV delay during other physiological states such as exercise. However,
for the purpose of genuine head-to-head comparison of several opti-
mization methods we had to select a posture suitable to all modalities
including echo, and which did not introduce unnecessary noise.We performed pressure optimization by measuring the changes
that occurred in pressure only for a short interval after a change in
the VV delay was programmed and did not measure pressure during
steady state pacing. We have recently shown [23] that any change in
pressure that occurs due to a change in AV delay decays to a lower
level only a few seconds later. This phenomenon means that signal-
to-noise ratio for pressure optimization is highest soon after a transi-
tion, and therefore systematically measured changes just shortly after
the VV delay change.
Moreover, we assessed the test–retest reproducibility of the opti-
mum over a short of period of time (within an hour) to guarantee that
any differences could not be attributed to large physiological or
volume changes between optimization sessions.
Finally, this is a study of AF only. Sinus rhythm may be different,
not least because changes in the VV delay always change the AV
delay on either the left or right side of the heart.
5. Conclusions
Singularity, reproducibility and plausibility are sine qua nons for an
optimization modality to undergo the next steps of mutual compari-
son between high-quality modalities, trialling for impact on clinical
endpoints, or adoption in clinical practice. Methods that do not have
these characteristics may be, unintentionally, a random selection
amongst settings. At best this could be useless. At worst, since the pa-
tients would be moving away from the vicinity of the optimum in
which they begin by factory default (0 ms), optimization might be
on average harmful.
Although LVOT VTI is the “ﬁnal common pathway” of all processes
within the heart and—being an index of cardiac output—is in principle
a perfect marker for pacemaker optimization, it has a poor singularity
and reproducibility even in an ideal research setting where time and
resources are artiﬁcially abundant. Its singularity and reproducibility
could be improved, but only by massively increasing the number of
replicates to a level intolerable even in a research setting and certainly
in a routine clinical setting.
In our study, only pressure optimization provided singularity, re-
producibility and plausibility. This study cannot truly compare pres-
sure optimization against ﬂow or QRS optimization, because neither
ﬂow nor QRS optimization were suitable candidates since they both
failed to fulﬁl criteria that are rudimentary.
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